Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:EWTX NASDAQ:LEGN NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$26.01+2.4%$23.43$19.69▼$28.35$4.35B0.81.38 million shs940,670 shsEWTXEdgewise Therapeutics$40.35-3.0%$38.06$12.30▼$48.40$4.48B0.27981,119 shs963,456 shsLEGNLegend Biotech$19.04-1.2%$28.56$16.24▼$42.26$3.58B0.342.22 million shs3.99 million shsWVEWAVE Life Sciences$5.89-0.5%$6.01$5.02▼$21.73$1.14B-1.292.30 million shs2.81 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+2.21%+1.20%+0.28%+12.00%+9.20%EWTXEdgewise Therapeutics+1.86%+7.19%+0.34%+34.24%+194.62%LEGNLegend Biotech-13.28%-16.98%-32.83%-18.21%-55.56%WVEWAVE Life Sciences+1.89%+3.32%+1.54%-21.28%-29.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$26.01+2.4%$23.43$19.69▼$28.35$4.35B0.81.38 million shs940,670 shsEWTXEdgewise Therapeutics$40.35-3.0%$38.06$12.30▼$48.40$4.48B0.27981,119 shs963,456 shsLEGNLegend Biotech$19.04-1.2%$28.56$16.24▼$42.26$3.58B0.342.22 million shs3.99 million shsWVEWAVE Life Sciences$5.89-0.5%$6.01$5.02▼$21.73$1.14B-1.292.30 million shs2.81 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+2.21%+1.20%+0.28%+12.00%+9.20%EWTXEdgewise Therapeutics+1.86%+7.19%+0.34%+34.24%+194.62%LEGNLegend Biotech-13.28%-16.98%-32.83%-18.21%-55.56%WVEWAVE Life Sciences+1.89%+3.32%+1.54%-21.28%-29.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.67Moderate Buy$33.1727.52% UpsideEWTXEdgewise Therapeutics 2.82Moderate Buy$48.7520.82% UpsideLEGNLegend Biotech 2.53Moderate Buy$55.29190.37% UpsideWVEWAVE Life Sciences 2.94Moderate Buy$26.41348.42% UpsideCurrent Analyst Ratings BreakdownLatest WVE, LEGN, ACAD, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2026LEGNLegend Biotech BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/28/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$65.007/27/2026LEGNLegend Biotech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$49.00 ➝ $28.007/27/2026LEGNLegend Biotech Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$58.007/27/2026LEGNLegend Biotech Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$63.00 ➝ $59.007/24/2026LEGNLegend Biotech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$49.00 ➝ $28.007/21/2026ACADACADIA Pharmaceuticals BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $36.007/21/2026ACADACADIA Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$24.00 ➝ $25.007/21/2026WVEWAVE Life Sciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/20/2026EWTXEdgewise Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.007/17/2026EWTXEdgewise Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B4.16$0.93 per share28.00$7.25 per share3.59EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/ALEGNLegend Biotech$1.14B3.10N/AN/A$5.43 per share3.51WVEWAVE Life Sciences$42.73M26.52N/AN/A$3.10 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2011.8227.0917.2234.30%9.61%7.07%8/4/2026 (Confirmed)EWTXEdgewise Therapeutics-$167.79M-$1.66N/AN/AN/AN/A-32.55%-31.04%8/6/2026 (Estimated)LEGNLegend Biotech-$296.80M-$0.68N/A12.21N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)WVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%7/30/2026 (Estimated)Latest WVE, LEGN, ACAD, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026LEGNLegend Biotech$0.0554N/AN/AN/A$356.01 millionN/A8/6/2026Q2 2026EWTXEdgewise Therapeutics-$0.48N/AN/AN/AN/AN/A8/4/2026Q2 2026ACADACADIA Pharmaceuticals$0.06N/AN/AN/A$295.51 millionN/A7/30/2026Q2 2026WVEWAVE Life Sciences-$0.31N/AN/AN/A$7.45 millionN/A5/13/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50-$0.46+$0.04-$0.46N/AN/A5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48EWTXEdgewise TherapeuticsN/A22.6122.61LEGNLegend BiotechN/A2.132.05WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%EWTXEdgewise TherapeuticsN/ALEGNLegend Biotech70.89%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%EWTXEdgewise Therapeutics21.30%LEGNLegend Biotech0.02%WVEWAVE Life Sciences24.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableEWTXEdgewise Therapeutics60107.59 million84.68 millionOptionableLEGNLegend Biotech2,965185.74 million185.70 millionOptionableWVEWAVE Life Sciences240192.40 million145.65 millionOptionableWVE, LEGN, ACAD, and EWTX HeadlinesRecent News About These CompaniesWAVE Life Sciences Ltd. $WVE Shares Sold by Elmind Capital LPJuly 28 at 4:00 AM | marketbeat.comAffinity Asset Advisors LLC Decreases Stake in WAVE Life Sciences Ltd. $WVEJuly 25 at 3:12 AM | marketbeat.comWave Life Sciences (WVE) Stock Looks Cheap On Price But Expensive On SalesJuly 24, 2026 | finance.yahoo.comWave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026July 23, 2026 | globenewswire.comZacks Research Upgrades WAVE Life Sciences (NASDAQ:WVE) to "Strong-Buy"July 23, 2026 | marketbeat.comWAVE Life Sciences (WVE) to Release Quarterly Earnings on ThursdayJuly 23, 2026 | americanbankingnews.comWAVE Life Sciences (WVE) to Post Earnings on ThursdayJuly 23, 2026 | marketbeat.comWave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?July 22, 2026 | zacks.comNew Strong Buy Stocks for July 22ndJuly 22, 2026 | zacks.com3 Promising Genomics Stocks to Add to Your Portfolio in 2026July 20, 2026 | zacks.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Moderate Buy" by AnalystsJuly 16, 2026 | marketbeat.comWAVE Life Sciences Ltd. $WVE Position Reduced by Emerald Advisers LLCJuly 14, 2026 | marketbeat.comEmerald Mutual Fund Advisers Trust Sells 600,136 Shares of WAVE Life Sciences Ltd. $WVEJuly 14, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading Down 8.3% - What's Next?July 10, 2026 | marketbeat.comWave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for RedomiciliationJuly 7, 2026 | globenewswire.comDoes Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?July 1, 2026 | zacks.comWave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM TrialJune 30, 2026 | insidermonkey.comWave Life Sciences Shareholders Approve Redomiciliation SchemeJune 26, 2026 | tipranks.comWave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic DiseasesJune 24, 2026 | globenewswire.comWave Life Sciences (WVE) Upgraded to Buy: Here's WhyJune 16, 2026 | zacks.comIs Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?June 13, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWVE, LEGN, ACAD, and EWTX Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$26.01 +0.62 (+2.44%) Closing price 04:00 PM EasternExtended Trading$26.02 +0.01 (+0.04%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Edgewise Therapeutics NASDAQ:EWTX$40.35 -1.25 (-3.00%) Closing price 04:00 PM EasternExtended Trading$40.35 +0.00 (+0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Legend Biotech NASDAQ:LEGN$19.04 -0.23 (-1.19%) Closing price 04:00 PM EasternExtended Trading$18.96 -0.07 (-0.39%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.WAVE Life Sciences NASDAQ:WVE$5.89 -0.03 (-0.51%) Closing price 04:00 PM EasternExtended Trading$5.96 +0.07 (+1.17%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
